Neoadjuvant chemotherapy in early-stage non-small cell lung cancer

Research output: Contribution to journalReview articlepeer-review


Of the patients that undergo complete resection of early-stage non-small cell lung cancer (NSCLC), 30-60% will die. Postoperative adjuvant chemotherapy has yet to demonstrate an unequivocal benefit and there are significant difficulties in administering postoperative chemotherapy to patients with the significant comorbidities found in NSCLC. Currently, several trials are evaluating the role of preoperative chemotherapy in stage I and II NSCLC. This paper reviews the rationale for this approach and potential future developments.

Original languageEnglish
Pages (from-to)229-235
Number of pages7
JournalExpert Review of Anticancer Therapy
Issue number2
StatePublished - 2001


  • Antineoplastic Combined Chemotherapy Protocols/therapeutic use
  • Biomarkers, Tumor/metabolism
  • Carcinoma, Non-Small-Cell Lung/classification
  • Chemotherapy, Adjuvant/methods
  • Clinical Trials as Topic
  • Humans
  • Lung Neoplasms/classification
  • Neoadjuvant Therapy/methods
  • Neoplasm Staging
  • Recurrence


Dive into the research topics of 'Neoadjuvant chemotherapy in early-stage non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this